Tumores Torácicos

Diretriz | Estratificação de risco de malignidade para nódulo pulmonar solitário.

5 Jul, 2022 | 11:45h

Malignancy risk stratification for solitary pulmonary nodule: A clinical practice guideline – Journal of Evidence-Based Medicine

Estudo randomizado | Furmonertinibe vs. gefitinibe como terapia de primeira linha para pacientes com câncer de pulmão de não pequenas células localmente avançado ou metastático positivo para mutação EGFR.

16 Jun, 2022 | 12:02h

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study – The Lancet Respiratory Medicine (link para o resumo – $ para o texto completo)

#ASCO22 – Estudo de braço único fase 2 | Adagrasibe em câncer de pulmão de não pequenas células abrigando uma mutação KRASG12C.

13 Jun, 2022 | 14:42h

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS^G12C Mutation – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comunicado de imprensa: Targeted drug achieves 43% response rate in KRAS-mutated lung cancer – Dana-Farber Cancer Institute

#ASCO22 – Estudo randomizado fase 2 | Ramucirumabe e pembrolizumabe vs. cuidado padrão no câncer de pulmão de não pequenas células avançado e previamente tratado com imunoterapia.

13 Jun, 2022 | 14:40h

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A – Journal of Clinical Oncology

Comentário: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network

Comentário no Twitter

📣 #ASCO22 simultaneous pub: Lung-MAP study finds ramucirumab ➕ pembro improved OS in pts w #NSCLC previously treated w/ immune ✔️point inhibitors & chemo. https://t.co/M0zL95ddxD @ReckampK @DrRoyHerbstYale #lcsm

— Journal of Clinical Oncology (@JCO_ASCO) June 3, 2022

Resumo das melhores evidências de ERAS (enhanced recovery after surgery) para pacientes submetidos a cirurgias de câncer de pulmão.

13 Jun, 2022 | 13:47h

Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations – Asia-Pacific Journal of Oncology Nursing

Conteúdos relacionados:

Guidelines for enhanced recovery after lung surgery: recommendations of the Enhanced Recovery After Surgery (ERAS^®) Society and the European Society of Thoracic Surgeons (ESTS) – European Journal of Cardio-Thoracic Surgery

Enhanced recovery programs in lung cancer surgery: systematic review and meta-analysis of randomized controlled trials – Cancer Management and Research

Clinical guidelines on perioperative management strategies for enhanced recovery after lung surgery – Translational Lung Cancer Research

Systematic Review and Meta-Analysis of Randomized, Controlled Trials on Preoperative Physical Exercise Interventions in Patients with Non-Small-Cell Lung Cancer – Cancers

Preoperative exercise training for patients with non‐small cell lung cancer – Cochrane Library

Estudo de autópsias: metástases cardíacas de tumores sólidos.

13 Jun, 2022 | 13:44h

Cardiac Metastasis From Solid Cancers: A 35-Year Single-Center Autopsy Study – Archives of Pathology & Laboratory Medicine

M-A | Radiocirurgia estereotáxica vs. radioterapia cerebral total em pacientes com doença metastática intracraniana e câncer de pulmão de pequenas células.

31 Mai, 2022 | 11:52h

Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comunicado de imprensa: Meta-Analysis Shows Targeted Radiation Therapy May Be as Effective as Standard Care for Small Cell Lung Cancer Patients with Brain Metastases – St. Michael’s Hospital

Estudo de fase 2, braço único | Sobrevida geral e análise de biomarcadores do nivolumabe neoadjuvante com quimioterapia no câncer de pulmão de não pequenas células operável estágio IIIA.

31 Mai, 2022 | 11:50h

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) – Journal of Clinical Oncology

Comentário no Twitter

In NADIM study of neoadj chemo + nivo for stage IIIA NSCLC, 3-y OS was 91%; low levels of pretreatment ctDNA and undetectable ctDNA after neoadjuvant therapy were predictive of OS (with HRs of 0.07 and 0.04, respectively) https://t.co/BIprSnDICd

— NatureRevClinOncol (@NatRevClinOncol) May 18, 2022

Estudo randomizado | Tiragolumabe com atezolizumabe vs. placebo com atezolizumabe como tratamento de primeira linha para câncer de pulmão de não pequenas células com expressão de PD-L1.

30 Mai, 2022 | 12:44h

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentário: First-line tiragolumab–atezolizumab promising for PD-L1-positive advanced NSCLC – Medicine Matters

Estudo randomizado | Adebrelimabe ou placebo com carboplatina e etoposídeo como tratamento de primeira linha para câncer de pulmão de pequenas células em estágio extenso.

30 Mai, 2022 | 12:40h

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)